Correlation Between Akari Therapeutics and Processa Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Akari Therapeutics and Processa Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Akari Therapeutics and Processa Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Akari Therapeutics PLC and Processa Pharmaceuticals, you can compare the effects of market volatilities on Akari Therapeutics and Processa Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Akari Therapeutics with a short position of Processa Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Akari Therapeutics and Processa Pharmaceuticals.

Diversification Opportunities for Akari Therapeutics and Processa Pharmaceuticals

0.64
  Correlation Coefficient

Poor diversification

The 3 months correlation between Akari and Processa is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Akari Therapeutics PLC and Processa Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Processa Pharmaceuticals and Akari Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Akari Therapeutics PLC are associated (or correlated) with Processa Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Processa Pharmaceuticals has no effect on the direction of Akari Therapeutics i.e., Akari Therapeutics and Processa Pharmaceuticals go up and down completely randomly.

Pair Corralation between Akari Therapeutics and Processa Pharmaceuticals

Given the investment horizon of 90 days Akari Therapeutics PLC is expected to under-perform the Processa Pharmaceuticals. In addition to that, Akari Therapeutics is 1.25 times more volatile than Processa Pharmaceuticals. It trades about -0.34 of its total potential returns per unit of risk. Processa Pharmaceuticals is currently generating about 0.11 per unit of volatility. If you would invest  98.00  in Processa Pharmaceuticals on September 17, 2024 and sell it today you would earn a total of  13.00  from holding Processa Pharmaceuticals or generate 13.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Akari Therapeutics PLC  vs.  Processa Pharmaceuticals

 Performance 
       Timeline  
Akari Therapeutics PLC 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Processa Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Processa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Akari Therapeutics and Processa Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Akari Therapeutics and Processa Pharmaceuticals

The main advantage of trading using opposite Akari Therapeutics and Processa Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Akari Therapeutics position performs unexpectedly, Processa Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Processa Pharmaceuticals will offset losses from the drop in Processa Pharmaceuticals' long position.
The idea behind Akari Therapeutics PLC and Processa Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Fundamental Analysis
View fundamental data based on most recent published financial statements